X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with NALWA SONS INV - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs NALWA SONS INV - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

NALWA SONS INV 
   Change

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES NALWA SONS INV INDOCO REMEDIES/
NALWA SONS INV
 
P/E (TTM) x 31.0 49.6 62.5% View Chart
P/BV x 3.7 1.9 194.8% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 INDOCO REMEDIES   NALWA SONS INV
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
NALWA SONS INV
Mar-14
INDOCO REMEDIES/
NALWA SONS INV
5-Yr Chart
Click to enlarge
High Rs360695 51.9%   
Low Rs249452 55.2%   
Sales per share (Unadj.) Rs119.071.5 166.4%  
Earnings per share (Unadj.) Rs8.455.5 15.1%  
Cash flow per share (Unadj.) Rs15.255.5 27.5%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7607.5 11.6%  
Shares outstanding (eoy) m92.155.14 1,792.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.68.0 32.0%   
Avg P/E ratio x36.410.3 352.5%  
P/CF ratio (eoy) x20.010.3 193.6%  
Price / Book Value ratio x4.30.9 456.7%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,0832,947 953.0%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1673 68,350.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968368 2,982.8%  
Other income Rs m400 13,233.3%   
Total revenues Rs m11,007368 2,991.1%   
Gross profit Rs m1,565360 434.1%  
Depreciation Rs m6330-   
Interest Rs m620-   
Profit before tax Rs m909361 252.1%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m13971 196.6%   
Profit after tax Rs m771285 270.4%  
Gross profit margin %14.398.0 14.6%  
Effective tax rate %15.319.6 78.0%   
Net profit margin %7.077.5 9.1%  
BALANCE SHEET DATA
Current assets Rs m5,7252,013 284.3%   
Current liabilities Rs m5,454113 4,846.4%   
Net working cap to sales %2.5517.0 0.5%  
Current ratio x1.017.9 5.9%  
Inventory Days Days6256 110.9%  
Debtors Days Days7231 231.8%  
Net fixed assets Rs m5,3070 5,307,380.0%   
Share capital Rs m18451 358.6%   
"Free" reserves Rs m6,3311,058 598.3%   
Net worth Rs m6,5163,123 208.7%   
Long term debt Rs m1,323297 445.5%   
Total assets Rs m11,9703,848 311.1%  
Interest coverage x15.6NM-  
Debt to equity ratio x0.20.1 213.5%  
Sales to assets ratio x0.90.1 958.8%   
Return on assets %7.07.4 93.9%  
Return on equity %11.89.1 129.6%  
Return on capital %12.410.4 119.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886116 762.8%  
From Investments Rs m-1,706-134 1,269.9%  
From Financial Activity Rs m1,31628 4,632.7%  
Net Cashflow Rs m49710 4,821.4%  

Share Holding

Indian Promoters % 59.2 55.4 106.9%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 12.5 0.6 2,083.3%  
FIIs % 6.0 4.2 142.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 39.6 56.6%  
Shareholders   12,805 23,884 53.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   GREENPLY IND  STC INDIA  TIL LTD  INDIABULLS FIN. SER.  INGERSOLL RAND  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Feb 21, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS